July 11, 2017 / TheNewswire / Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of RwE Growth Partners, Inc. to evaluate the Company’s $1.50 million investment into its 80% owned research arm, Cannevert Therapeutics Ltd. (CTL). RwE Growth Partners expects to complete its evaluation within the next week in conjunction with the Company’s annual audit.

 

Veritas is also pleased to announce the appointment of the Company’s Chief Financial Officer, David Alexander to the Company’s Board of Directors. Mr. Alexander is replacing David Greenway, who has resigned from his position to focus on other ventures, but will remain on the Company’s Advisory Board.

 

About Veritas Pharma Inc.

 

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

 

About Cannevert Therapeutics Ltd.

 

CTL was a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. Veritas, through its investment of $1.5 million, in CTL as of April 2017 has obtained an 80% ownership interest in CTL. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.

 

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

 

For more information, please visit our website: www.veritaspharmainc.com

 

On behalf of the Board of Directors; Veritas Pharma Inc.

 

"Dr. Lui Franciosi"

Dr. Lui Franciosi

Chief Executive Officer

 

Further information about the Company is available on our website at www.veritaspharmainc.com  or under our profile on SEDAR at www.sedar.com  and on the CSE website at www.thecse.com

 

Investor and Public Relations Contact

Veritas Pharma Inc.

Sam Eskandari

Telephone: +1.416.918.6785

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

 

The CSE has not reviewed, nor approved or disapproved the content of this press release.